244 related articles for article (PubMed ID: 32539877)
1. Oral vancomycin prophylaxis against recurrent
Zacharioudakis IM; Zervou FN; Dubrovskaya Y; Phillips MS
Infect Control Hosp Epidemiol; 2020 Aug; 41(8):908-913. PubMed ID: 32539877
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
Johnson SW; Brown SV; Priest DH
Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
[TBL] [Abstract][Full Text] [Related]
3. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.
Stevens VW; Khader K; Echevarria K; Nelson RE; Zhang Y; Jones M; Timbrook TT; Samore MH; Rubin MA
Clin Infect Dis; 2020 Jul; 71(3):645-651. PubMed ID: 31504328
[TBL] [Abstract][Full Text] [Related]
4. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
5. Oral vancomycin for Clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant.
Altemeier OJ; Konrardy KT
Transpl Infect Dis; 2022 Apr; 24(2):e13790. PubMed ID: 35014136
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of
Knight EM; Schiller DS; Fulman MK; Rastogi R
J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479
[TBL] [Abstract][Full Text] [Related]
7. Oral vancomycin prophylaxis for the prevention of
Babar S; El Kurdi B; El Iskandarani M; Haddad I; Imam Z; Alomari M; Myers J; Moorman J
Infect Control Hosp Epidemiol; 2020 Nov; 41(11):1302-1309. PubMed ID: 32594929
[TBL] [Abstract][Full Text] [Related]
8. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.
Caroff DA; Menchaca JT; Zhang Z; Rhee C; Calderwood MS; Kubiak DW; Yokoe DS; Klompas M
Infect Control Hosp Epidemiol; 2019 Jun; 40(6):662-667. PubMed ID: 31030679
[TBL] [Abstract][Full Text] [Related]
9. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
[TBL] [Abstract][Full Text] [Related]
10. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
11. Implementation of routine Clostridioides difficile infection (CDI) primary prophylaxis in lung transplant recipients.
Fitzmaurice MG; Hohlfelder B; Srinivas P; Rudoni M; Brizendine KD; Budev M
Clin Transplant; 2023 Sep; 37(9):e15079. PubMed ID: 37477286
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
Carignan A; Poulin S; Martin P; Labbé AC; Valiquette L; Al-Bachari H; Montpetit LP; Pépin J
Am J Gastroenterol; 2016 Dec; 111(12):1834-1840. PubMed ID: 27619835
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
[TBL] [Abstract][Full Text] [Related]
14. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
[TBL] [Abstract][Full Text] [Related]
15. Houston, We Have a Problem: Reports of Clostridioides difficile Isolates With Reduced Vancomycin Susceptibility.
Greentree DH; Rice LB; Donskey CJ
Clin Infect Dis; 2022 Oct; 75(9):1661-1664. PubMed ID: 35653393
[TBL] [Abstract][Full Text] [Related]
16. Oral Vancomycin as Secondary Prophylaxis for
Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP
Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867
[TBL] [Abstract][Full Text] [Related]
17. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.
Miller M; Bernard L; Thompson M; Grima D; Pepin J
Infect Control Hosp Epidemiol; 2010 Jul; 31(7):710-5. PubMed ID: 20518636
[TBL] [Abstract][Full Text] [Related]
18. Impact of oral vancomycin treatment duration on rate of
Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization.
Choi HK; Kim KH; Lee SH; Lee SJ
J Korean Med Sci; 2011 Jul; 26(7):859-64. PubMed ID: 21738336
[TBL] [Abstract][Full Text] [Related]
20. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.
Brown CC; Manis MM; Bohm NM; Curry SR
Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
